Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 6;12(2):185.
doi: 10.3390/v12020185.

Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines

Kara-Lee Aves  1 , Louise Goksøyr  1   2 , Adam F Sander  1   2
Affiliations
Review

Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines

Kara-Lee Aves et al. Viruses. .

Abstract

Capsid-like particles (CLPs) are multimeric, repetitive assemblies of recombinant viral capsid proteins, which are highly immunogenic due to their structural similarity to wild-type viruses. CLPs can be used as molecular scaffolds to enable the presentation of soluble vaccine antigens in a similar structural format, which can significantly increase the immunogenicity of the antigen. CLP-based antigen display can be obtained by various genetic and modular conjugation methods. However, these vary in their versatility as well as efficiency in achieving an immunogenic antigen display. Here, we make a comparative review of the major CLP-based antigen display technologies. The Tag/Catcher-AP205 platform is highlighted as a particularly versatile and efficient technology that offers new qualitative and practical advantages in designing modular CLP vaccines. Finally, we discuss how split-protein Tag/Catcher conjugation systems can help to further propagate and enhance modular CLP vaccine designs.

Keywords: capsid, antigen display, virus-like particle, vaccine, platform.

PubMed Disclaimer

Conflict of interest statement

A.F.S. is listed as co-inventor on a patent application covering the AP205 CLP vaccine platform technology (WO2016112921 A1) licensed to AdaptVac. A.F.S and L.G. are currently partially employed in AdaptVac. K-L.A. declares no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Doherty M., Buchy P., Standaert B., Giaquinto C., Prado-Cohrs D. Vaccine impact: Benefits for human health. Vaccine. 2016;34:6707–6714. doi: 10.1016/j.vaccine.2016.10.025. - DOI - PubMed
    1. Lam E., McCarthy A., Brennan M. Vaccine-preventable diseases in humanitarian emergencies among refugee and internally-displaced populations. Hum. Vaccines Immunother. 2015;11:2627–2636. doi: 10.1080/21645515.2015.1096457. - DOI - PMC - PubMed
    1. Marin M., Nguyen H.Q., Langidrik J.R., Edwards R., Briand K., Papania M.J., Seward J.F., LeBaron C.W. Measles Transmission and Vaccine Effectiveness during a Large Outbreak on a Densely Populated Island: Implications for Vaccination Policy. Clin. Infect. Dis. 2006;42:315–319. doi: 10.1086/498902. - DOI - PubMed
    1. Greaves W.L., Orenstein W.A., Hinman A.R., Nersesian W.S. Clinical efficacy of rubella vaccine. Pediatr. Infect. Dis. J. 1983;2:284–286. doi: 10.1097/00006454-198307000-00005. - DOI - PubMed
    1. Amanna I.J., Slifka M.K., Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol. Rev. 2006;211:320–337. doi: 10.1111/j.0105-2896.2006.00392.x. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources